Form 4: Ligand Pharma Director Sells Shares Under 10b5-1 Plan

Ligand Pharmaceuticals Director John W. Kozarich sold 467 shares of common stock on October 1, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• John W. Kozarich, a Director of Ligand Pharmaceuticals Inc. (LGND), reported the sale of 467 shares of common stock.
• The transactions occurred on October 1, 2025, and were executed under a Rule 10b5-1 trading plan adopted on March 7, 2025.
• The shares were sold in multiple transactions at weighted-average prices ranging from $177.6048 to $181.1838.
• Following these transactions, Mr. Kozarich beneficially owns 45,055 shares of common stock.

Sentiment

Score: 5

Explanation: The sale of shares by a director, while reducing insider ownership, was conducted under a pre-arranged 10b5-1 trading plan, suggesting it is not based on new material non-public information and thus has a neutral impact on sentiment.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, which indicates the transactions were scheduled in advance and not based on new material non-public information.

Negatives

• A director reduced their direct ownership in the company by selling 467 shares.

Risks

• Reduced insider ownership could be perceived negatively by some investors, although this is mitigated by the pre-arranged 10b5-1 plan.

Future Outlook

This filing, an insider transaction report, does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The reported transactions were executed pursuant to a written trading plan adopted on March 7, 2025, in accordance with Rule 10b5-1.

Industry Context

Insider transactions, particularly those under Rule 10b5-1 plans, are common occurrences in publicly traded companies and are generally viewed as routine personal financial management rather than signals of company-specific or industry-wide shifts.

Stakeholder Impact

• Shareholders: May observe a slight reduction in insider ownership, though the pre-planned nature of the sale typically minimizes concerns.
• Investment Professionals: Will note the transaction as part of routine insider activity, unlikely to alter investment theses unless part of a larger pattern.

Key Dates

Recommendation

The reported insider sales were executed under a pre-arranged 10b5-1 trading plan, indicating a scheduled divestment rather than a reaction to new material information. This type of transaction typically has a neutral impact on investment sentiment and does not warrant a change in investment recommendation based solely on this filing.

Keywords

Ligand Pharmaceuticals, LGND, Insider Trading, Form 4, Stock Sale, Director, John W. Kozarich, 10b5-1 Plan, Equity Transaction